StockData
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. (TPST) stock

TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$0.31−0.02 (-5.50%)

Close on Nov 18, 2026Market cap $4.58MP/E –Yield –

Tempest Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Tempest Therapeutics's revenue for the twelve months ending Sep 30, 2018 was $294.00K, down 9.3% year over year. For fiscal 2017 it was $295.00K, down 54.8% from the year before. The highest annual figure on record is $653.00K in fiscal 2016.

Annual revenue

PeriodPeriod endValueChange
FY2017Dec 31, 2017$295.00K-54.8%
FY2016Dec 31, 2016$653.00K+135.7%
FY2015Dec 31, 2015$277.00K–
FY2014Dec 31, 2014$0–
FY2013Dec 31, 2013$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2018Sep 30, 2018$55.00K-1.8%
Q2 FY2018Jun 30, 2018$81.00K-3.6%
Q1 FY2018Mar 31, 2018$67.00K+6.3%
Q4 FY2017Dec 31, 2017$91.00K-24.8%
Q3 FY2017Sep 30, 2017$56.00K-71.6%
Q2 FY2017Jun 30, 2017$84.00K–
Q1 FY2017Mar 31, 2017$63.00K–
Q4 FY2016Dec 31, 2016$121.00K–
Q3 FY2016Sep 30, 2016$197.00K–

More Tempest Therapeutics figures

See a number that looks wrong?